Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 08:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal...
March 19, 2026 08:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th...
March 05, 2026 08:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative...
November 05, 2025 16:30 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
April 08, 2024 07:45 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity — — Patient enrollment expected to be completed in 2024 — ...
June 13, 2022 07:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

-- First Site Will Enroll First Patient in the Clinical Study-- MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:...
November 10, 2021 06:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer

MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
November 04, 2021 21:21 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market

Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “BRTX” November 5, 2021 MELVILLE, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....
September 02, 2021 09:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program

Issued Patent Grants Protection for an Implantable Scaffold using Brown Adipose Derived Stem Cells and Methods of Use MELVILLE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies,...
August 31, 2021 09:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program

Patent Issued Grants Protection for Deriving Brown Adipocytes from Brown Adipose (Fat)-Derived Stem Cells MELVILLE, N.Y., Aug. 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the...